Literature DB >> 26142488

Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.

Ivana Pibiri1, Laura Lentini2, Raffaella Melfi2, Giulia Gallucci2, Andrea Pace3, Angelo Spinello2, Giampaolo Barone1, Aldo Di Leonardo4.   

Abstract

Premature stop codons are the result of nonsense mutations occurring within the coding sequence of a gene. These mutations lead to the synthesis of a truncated protein and are responsible for several genetic diseases. A potential pharmacological approach to treat these diseases is to promote the translational readthrough of premature stop codons by small molecules aiming to restore the full-length protein. The compound PTC124 (Ataluren) was reported to promote the readthrough of the premature UGA stop codon, although its activity was questioned. The potential interaction of PTC124 with mutated mRNA was recently suggested by molecular dynamics (MD) studies highlighting the importance of H-bonding and stacking π-π interactions. To improve the readthrough activity we changed the fluorine number and position in the PTC124 fluoroaryl moiety. The readthrough ability of these PTC124 derivatives was tested in human cells harboring reporter plasmids with premature stop codons in H2BGFP and FLuc genes as well as in cystic fibrosis (CF) IB3.1 cells with a nonsense mutation. Maintaining low toxicity, three of these molecules showed higher efficacy than PTC124 in the readthrough of the UGA premature stop codon and in recovering the expression of the CFTR protein in IB3.1 cells from cystic fibrosis patient. Molecular dynamics simulations performed with mutated CFTR mRNA fragments and active or inactive derivatives are in agreement with the suggested interaction of PTC124 with mRNA.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CFTR gene; Cystic fibrosis; Fluorinated oxadiazole; Green fluorescent protein; Nonsense mutation; PTCs readthrough

Mesh:

Substances:

Year:  2015        PMID: 26142488     DOI: 10.1016/j.ejmech.2015.06.038

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  20 in total

Review 1.  Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.

Authors:  Kevin G Chen; Pingyu Zhong; Wei Zheng; Jeffrey M Beekman
Journal:  Drug Discov Today       Date:  2019-06-04       Impact factor: 7.851

Review 2.  Small molecules as therapeutic agents for inborn errors of metabolism.

Authors:  Leslie Matalonga; Laura Gort; Antonia Ribes
Journal:  J Inherit Metab Dis       Date:  2016-12-13       Impact factor: 4.982

Review 3.  Shwachman-Diamond Syndrome: Molecular Mechanisms and Current Perspectives.

Authors:  Valentino Bezzerri; Marco Cipolli
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

4.  Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs).

Authors:  Marco Tutone; Ivana Pibiri; Riccardo Perriera; Ambra Campofelice; Giulia Culletta; Raffaella Melfi; Andrea Pace; Anna Maria Almerico; Laura Lentini
Journal:  ACS Med Chem Lett       Date:  2020-02-18       Impact factor: 4.345

5.  A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease.

Authors:  Darren M Hutt; Salvatore Loguercio; Alexandre Rosa Campos; William E Balch
Journal:  J Mol Biol       Date:  2018-06-18       Impact factor: 5.469

6.  A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsense mutation read-through agents.

Authors:  Michal Caspi; Anastasia Firsow; Raja Rajkumar; Nir Skalka; Itay Moshkovitz; Ariel Munitz; Metsada Pasmanik-Chor; Hagar Greif; Dalia Megido; Revital Kariv; Daniel W Rosenberg; Rina Rosin-Arbesfeld
Journal:  J Mol Med (Berl)       Date:  2015-12-01       Impact factor: 4.599

7.  Neuropathies of Stüve-Wiedemann Syndrome due to mutations in leukemia inhibitory factor receptor (LIFR) gene.

Authors:  Alexandra E Oxford; Cheryl L Jorcyk; Julia Thom Oxford
Journal:  J Neurol Neuromedicine       Date:  2016

8.  Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study.

Authors:  Marco Tutone; Ivana Pibiri; Laura Lentini; Andrea Pace; Anna Maria Almerico
Journal:  ACS Med Chem Lett       Date:  2019-02-07       Impact factor: 4.345

9.  Serum starvation enhances nonsense mutation readthrough.

Authors:  Amnon Wittenstein; Michal Caspi; Yifat David; Yamit Shorer; Prathamesh T Nadar-Ponniah; Rina Rosin-Arbesfeld
Journal:  J Mol Med (Berl)       Date:  2019-11-15       Impact factor: 4.599

Review 10.  CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.

Authors:  Miquéias Lopes-Pacheco
Journal:  Front Pharmacol       Date:  2016-09-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.